World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 8
Page: 183-192

OPTIMIZING RENAL SAFETY IN HIGH -DOSE METHOTREXATE THERAPY: A COMPREHENSIVE REVIEW

Dr. Deepak Kumar Punna*, Dr. Sumana Chatla

Dept. of Pharmacy Practice, KVK College of Pharmacy, Surmaiguda, Abdullapurmet, RR District, Telangana, India.

Article Received: 15 June 2026 | | Article Revised: 06 July 2026 | | Article Accepted: 27 July 2026

***Corresponding Author: Dr. Deepak Kumar Punna**
Dept. of Pharmacy Practice, KVK College of Pharmacy, Surmaiguda, Abdullapurmet, RR District, Telangana, India.
DOI: https://doi.org/10.5281/zenodo.21704370

How to cite this Article: Dr. Deepak Kumar Punna, Dr. Sumana Chatla (2026) OPTIMIZING RENAL SAFETY IN HIGH -DOSE METHOTREXATE THERAPY: A COMPREHENSIVE REVIEW. World Journal of Pharmaceutical Science and Research, 5(8), 183-192.

ABSTRACT

Methotrexate (MTX) remains the first-line treatment option even in large doses (HD-MTX) for solid tumors and hematologic malignancies. However, MTX related toxicity to the kidneys has been a major clinical issue even with the use of effective drugs; this has caused among other things increased hospital stays, delays in treatment, and acute kidney injury (AKI) in some cases of allergic reactions. As the kidneys are the main organs that eliminate MTX, the renal function is crucial for the safe use of the drug. • This review integrates the extensive data from the recent clinical trials (2020–2025) and mechanistic studies to provide the most up-to-date knowledge of MTX nephrotoxicity, risk factors, novel biomarkers, and changing treatment paradigms. The review focuses on and emphasizes the significant clinical outcomes of recent studies, discusses treatment techniques such as glucarpidase, hydration schedules, and urine alkalinization, and even evaluates the new methods of AI-backed prediction models and personalized dosing. It is the aim of the review to support practitioners, pharmacists, and cancer doctors in making substantial progress in the prevention, early detection, and best management of MTX-induced renal impairment.

KEYWORDS: Design of Experiments, Quality by Design, Pharmaceutical manufacturing, Process optimization.

INTRODUCTION

Methotrexate, an antimetabolite drug, is usually prescribed for solid tumors like osteosarcoma, lymphoma, acute lymphoblastic leukemia (ALL), and other cancerous tumors. Because of its narrow therapeutic range, high-dose methotrexate (HD-MTX) commonly characterized by dosages exceeding 500 mg/m², necessitates extensive supportive care. 80-90% of MTX is detoxified and expelled through the kidneys in the same form by tubular secretion and glomerular filtration. Any drop in kidney function causes a reduction in MTX excretion leading to an increase in

toxicity and a longer duration of systemic exposure. 80–90% of administered methotrexate is eliminated unchanged through renal tubular secretion and glomerular filtration, making renal function critical for safe therapy.

Among the various complicated toxic effects of MTX, the reduction in renal blood flow, swelling of the nephrons due to oxidation, the killing of kidney tubule cells by the drug directly, and the accumulation of crystals in the renal tubules are mentioned among the most important. Nephrotoxicity from MTX still happens in patients 2–12% of the time in the HD-MTX cycle, even though monitoring improvements and supportive techniques have helped to ensure that severe toxicities do not occur in the last decade. The current study highlights the need for personalized medicine, biomarker-based risk assessment, and immediate salvage therapy. Methotrexate is an antimetabolite widely used in the treatment of solid tumors such as osteosarcoma and hematological malignancies including lymphoma and acute lymphoblastic leukemia. High-dose methotrexate (HD-MTX), typically defined as doses exceeding 500 mg/m², requires intensive supportive care due to its narrow therapeutic index. 80–90% of administered methotrexate is eliminated unchanged through renal tubular secretion and glomerular filtration, making renal function a critical determinant of drug clearance and safety. Any reduction in renal function can lead to delayed methotrexate elimination, prolonged systemic exposure, and increased toxicity, including acute kidney injury (AKI).

Methotrexate Pharmacology in Relation to Nephrotoxicity

As a dihydrofolate reductase (DHFR) inhibitor, MTX stops DNA production and folate metabolism. Its toxicity is remarkably influenced by its pharmacokinetics.

Distribution and Absorption HD-MTX needs to be given intravenously. MTX binds extensively to albumin thus amplifying the risk for the hypoalbuminemia patients to get harmed. Methotrexate pharmacokinetics vary depending on the route of administration and the presence of third-space effusions.

Clearance of the Kidneys 80-90% are excreted through the kidneys in 24-48 hours. The clearance is slowed down by competitive inhibition which is caused by certain drugs namely penicillin's, PPIs, and NSAIDs.

Polyglutamation The intracellular MTX polyglutamates that are formed increase both toxicity and activity.

Renal Tubule Precipitation One of the renal tubular blockage mechanisms is the precipitation of MTX and its metabolite 7-hydroxymethotrexate (7-OH-MTX) in acidic urine. This way, MTX is especially vulnerable to nephrotoxic outcomes due to its pharmacokinetic dependence on renal function.

Protein Binding: Methotrexate exhibits extensive binding to serum albumin, and alterations in protein binding can significantly influence the free fraction of the drug and its toxicity. Conditions such as hypoalbuminemia increase unbound methotrexate levels, thereby enhancing renal and systemic toxicity. Several pharmacokinetic studies have demonstrated that protein binding interactions, especially in the presence of nonsteroidal anti-inflammatory drugs and other competing agents, may alter methotrexate disposition and clearance.

Route of administration / distribution subsection

The pharmacokinetics of methotrexate are influenced by the route of administration and the presence of third-space effusions such as ascites or pleural effusions. These compartments act as reservoirs, prolonging methotrexate exposure and increasing the risk of delayed clearance and toxicity. Clinical pharmacokinetic studies have demonstrated

significant variability in methodology of methodology of methodology of methodology of methodology of methotrexate absorption, distribution, and elimination depending on shifts. Traction route and fluid shifts.

II. Mechanisms of Methotrexate-Induced Nephrotoxicity

MTX nephrotoxicity is the result of many overlapping mechanisms:

- **Intratubular Crystallization:** One of the principal mechanisms of methotrexate-induced nephrotoxicity is intratubular crystallization. Methotrexate and its metabolite 7-hydroxymethotrexate exhibit poor solubility in acidic urine, leading to crystal precipitation within renal tubules. This process results in tubular obstruction, inflammation, and acute tubular necrosis. Experimental and clinical evidence consistently identifies crystal nephropathy as a dominant mechanism of methotrexate-associated renal injury.
- **Toxicity to Direct Tubular Epithelium:** MTX induces apoptosis of the proximal tubule cells. The damage to the cells is done through ATP depletion, ROS production, and mitochondrial dysfunction.
- **Vasoconstriction:** The kidneys cause a dip in GFR and renal blood flow.
- **Pathways of Inflammation:** It is shown that the TNF-α, IL-1β, and NF-κB pathways are activated.
- **Renal Transporters Are Affected:** The elimination of MTX is hindered to a greater extent when the organic anion transporters (OAT1, OAT3) are dysfunctional.
- **DRUG–DRUG INTERACTIONS INCREASING METHOTREXATE**

NEPHROTOXICITY

Several pharmacokinetic and clinical studies have demonstrated that concomitant administration of interacting medications can significantly impair methotrexate clearance. Drugs such as NSAIDs, proton pump inhibitors, and sulfonamides compete for renal tubular secretion pathways, leading to delayed elimination and increased systemic exposure. These interactions are well documented and contribute substantially to methotrexate-induced nephrotoxicity.

Risk Factors for Methotrexate-Induced Nephrotoxicity

Category	Specific Risk Factor	Clinical impact
Patient related	Genetic types include preexisting renal impairment, aging, obesity, hypoalbuminemia, fluid deficit, and genetics. polymorphism (SLCO1B1, ABCG2)	Delayed MTX clearance, increased risk of AKI
Disease related	High quantities, tumor lysis syndrome, hepatic dysfunction	Increases the toxicity of MTX because of metabolic stress
Drug Related	NSAIDs, PPIs, sulphonamides, aminoglycosides and cisplatin are five potential nephrotoxins.	Renal clearance of MTX is decreased in the presence of another nephrotoxic agent.
Related to Therapy	Acidic urine (pH <7), insufficient fluid intake, and high-dose MTX (>12–15 g/m²) are the conditions that can be changed as these factors are modifiable; and so decreasing nephrotoxicity can be achieved by optimizing these.	Preventable; reducing the incidence of nephrotoxicity by an improved means is possible in this respect.

Drug–Drug Interactions Increasing Methotrexate Nephrotoxicity

Interacting Drug/Class	Mechanism of Interaction	Clinical Impact on MTX Nephrotoxicity
NSAIDs (Ibuprofen, Diclofenac, Naproxen)	Preventable; reducing the incidence of nephrotoxicity by an improved means is possible in this respect.	Increased MTX plasma levels → higher risk of AKI, mucositis, myelosuppression
Penicillins (Amoxicillin, Piperacillin)	Compete with MTX for renal tubular secretion	Delayed MTX elimination severe nephrotoxicity & bone marrow suppression

Proton Pump Inhibitors (Omeprazole, Pantoprazole)	Inhibit the H+/K+ ATPase transporters in the kidneys to reintroduce the secretion of MTX.	Accumulation of MTX; prolonged half-life renal toxicity ←
Trimethoprim-Sulfamet hoxazole (TMP-SMX)	Consisting of a delivery of entourage.	Increased AKI risk, pancytopenia and very severe mucositis.
Loop Diuretics (Furosemide)	The previously mentioned can reduce from current types of volume blood changes, intrapleural perfusion, and methodology.	Incidental nephrotoxicity; potentiates renal damage caused by MTX

Clinical Presentation and Diagnostic Markers of MTX Nephrotoxicity

Clinical Feature	Detail	Clinical Relevance
Symptoms	Oliguria, nausea, vomiting, mucositis, edema	Usually appears 24–48 h after HD-MTX
Laboratory findings	Methotrexate-induced nephrotoxicity typically presents within 24–48 hours following HD-MTX administration. Laboratory findings include rising serum creatinine and blood urea nitrogen levels, delayed methotrexate clearance, hyperuricemia, and crystalluria. Delayed clearance accompanied by renal function deterioration confirms the diagnosis of acute kidney injury and necessitates prompt intervention	Confirms AKI and delayed MTX elimination
Emerging Biomarkers	NGAL, KIM-1, cystatin C, TIMP-2×IGFBP7	Diagnosing kidney damage 12–24 h before creatinine increases allows for immediate treatment.

Special Populations

Certain populations are at a higher risk of MTX-induced nephrotoxicity due to pharmacokinetics and physiological differences.

a. **Older patients:** The main factor is the decreased renal of the drug due to age. The risk of drug interactions is increased by polypharmacy.

b. **Pre-existing renal dysfunction:** Even slight CKD can double the risk of toxicity, so it is best to avoid MTX in high doses and watch closely.

c. **Children:** Pediatric patients exhibit considerable variability in methodology of pharmacokinetics due to ongoing renal maturation and differences in tubular secretion. These factors increase susceptibility to delayed methotrexate clearance and toxicity, particularly in high-dose regimens. Clinical studies in children with acute lymphoblastic leukemia have highlighted an increased risk of nephrotoxicity and systemic adverse effects when clearance is impaired.

d. **Obese Patients:** There is a change in drug distribution Dosing based on body surface area (BSA) may lead to overestimation of the safe dose.

e. **Low Albumin:** More unbound MTB to more unbound MTX leads to increased toxicity This condition is common in patients with advanced cancer or malnutrition.

f. **Nephrotoxic Agents**: Concurrently Vancomycin aminoglycosides, cisplatin, etc. The primary effect of these drugs is that they damage kidneys and lead to the delayed excretion of MTX through the same route.

g. **Genetic Polymorphisms: Variants** in SLCO1B1, MTHFR, and ABCC2 genes can come with differences in MA transport and metabolism levels.

h. **Liver failure:** More of the drug in the body because of less active metabolism.

i. **Poorly hydrated or dehydrated:** Patient with renal perfusion reduction may get MTX crystal nephropathy.

Key Clinical Trials on Methotrexate Nephrotoxicity (2020–2025)

Year	Design	Population	Intervention	Outcomes
2024/NCT03684980	Pilot study	CNS Lymphoma patients on HD- MTX	Low dose glucarpidase (1,000–2,000	MTX <100 nmol/L in all cycles; outpatient feasible; prevented nephrotoxicity
2023	Multi centered observation	Adults' with MTX-AKI	Glucarpidase vs Standard Care	Improved renal recovery 2.7×; reduced dialysis and hospital stay
2021	Investigator-Initiated	HD- MTX patients at high AKI risk	Flat dose glucarpidase	>95% MTX reduction; minimal adverse effects
2022	RCT	Pediatric All	Enhanced hydration ≥3 L/m²/day	Reduced AKI incidence by 60%; improved clearance
2023	RCT	Adults on HD-MTX	Urine alkalinization Bicarbonate vs tromethamine	Sodium bicarbonate superior; faster alkalinization, lower nephrotoxicity
2021 / NCT00001298	Phase II	MTX delaye d clearance / overdose	Glucarpidase + thymidine rescue	Rapid MTX drop >98%. prevented life-threatening. toxicity
2020–2024	Prospective Biomarker Study	HD-MTX patients	Serial NGAL / cystatin C monitoring	Early detection of AKI 12–24 h before creatine rise
2023	Cohort study	Patient with AKI + toxic MTX	Half-dose glucarpidase (~25 U/kg)	MTX fell 97–98%; renal recovery in most
2022	Retrospective	Children with prior MTX-AKI	Re-challenge HD-MTX after glucarpidase rescue	13/20 safely re-challenged;

RESULTS

Frequency and Intensity

- MTX-related nephrotoxicity was observed in 2–12% of HD-MTX cycles across the 38 studies considered.
- 1-3% of people had severe AKI that necessitated the use of glucarpidase.

Highest Risk Elements Found

- The most common risk factors were previous kidney damage (reported by 27 studies), dehydration (22 studies), consumption of NSAIDs or PPIs together (20 studies), acidic urine (19 studies), genetic variations affecting MTX transport (12 studies), and these factors often predicted delayed MTX excretion.

Trends in Mechanisms

- Almost all animal studies report that nephrotoxicity is due to crystal deposition in the tubules. Indirectly damaging proximal tubule, Increasing inflammatory cytokines due to oxidative damage, malfunctioning transporters, the most reported mechanism crystal nephropathy.

Preventive Strategies' Effectiveness Analysis of interventional studies revealed: Intensive hydration resulted in a decrease of 50-65% in the incidence of AKI. Urine alkalinization (pH>7) led to a 70% reduction in crystal formation.

Leucovorin rescue reduced systemic toxicity but did not always avert kidney injury. In all situations, glyceridase was effective in reducing the level of MTX.

Early Detection and Biomarkers

- The detection of renal damage was along the lines of the very early markers such as NGAL, KIM-1, and cystatin C (12-24 hours before the rise of creatinine). These markers demonstrated an extraordinarily strong predictive ability for high-risk patients.

Early intervention consistently led to the improvement of clinical outcomes:

- Less need for dialysis, shorter hospitalization periods, and avoidance of deaths due to MTX All these discoveries indicate a shift in HD-MTX management to initiative-taking supervision and personalized renal protection strategies.

Therapeutic Strategies to Prevent and Manage Methotrexate-Induced Nephrotoxicity

Renal replacement therapy has a limited role in the management of methotrexate toxicity. Conventional hemodialysis and peritoneal dialysis are often ineffective due to the binding method of protein and extensive tissue distribution. Clinical reports indicate that dialysis alone does not reliably reduce methotrexate levels, emphasizing the need for alternative rescue strategies.

S. No	Strategy	Mechanism	Implementation	Outcome
1	Hydration	Serves to support urine flow and decrease methotrexate concentration in renal tubules.	IV for 2.5-3.5 L/m²/day should start 12 h prior to HD-MTX and should be continued ≥48 h post infusion.	It reduces AKI incidence by 50-65%, by enhancing MTX clearance.
2	Urine alkalinization	Prevents MTX and 7-OH-MTX crystallization	Maintain urine pH at 7.0 by administration of sodium bicarbonate solution; pH should be checked at every 4-6 h.	Significantly prominent is the assumption of a frantically falling. MTX nephropathy risk.
3	Leucovorin Rescue	Folinic acid bypasses DHFR inhibition	It should be started 24 h after the administration of a high dose of MTX and adjusted according to MTX serum levels.	Mitigates systemic toxicities (mucositis, myelosuppression), moderate efficacy for solitary kidney damage.
4	Renal Replacement Therapy	Removes MTX from circulation in severe AKI	High-flux hemodialysis supports unstable patients.	Rescue therapy for severe AKI specifically not responding to glucarpidase.
5	Therapeutic Drug Monitoring	Guides timely interventions	Alternative to measure MTX levels at 24, 48, and 72 hours, then adjust leucovorin or glucarpidase dose accordingly.	Rapid recognition of perpetuating renal failure is instrumental in avoiding poisons from reaching other organs.
6	Optimized supportive care	Corrects the electrolyte imbalances while managing the concomitant diseases.	Monitor K+, Ca2+, Mg2+; ensure. nutrition and fluid. balance	Supports postoperative renal recovery by reducing postoperative complications.
7	Pharmacogenomics and Precision Dosing	It may indicate the presence of an increased risk for nephrotoxicity in a patient.	SLCO1B1/ABCG2 genotyping, ethotrexate dose adjustment; ALBbased clearance prediction.	Improves safety; reduces AKI and delayed clearance; facilitates. personalized therapy
8	Glucarpidase	It breaks down the circulating MTX to make it inert. The use of glucarpidase and	Indications include intolerance to delayed clearance of MTX or associated renal	The rapid elimination of methotrexate levels in the plasma is seen to be life-saving management; it

		extracorporealtreatments in methotrexate toxicity has been standardized through international guideline methodologies. Recommendations from expert workgroups outline indications for enzymatic and extracorporeal rescue therapies in cases of delayed clearance and renal impairment, providing a structured approach to life-threatening toxicity management	impairment; a single dose must be administered intravenously (50 U/kg in one medium dose or 25 U/kg as low dose)	rescues kidney function.

EMERGENCY AND OVERDOSE MANAGEMENT

Emergency management strategies for life-threatening methotrexate overdose have been well described in clinical case series and reports. These include intrathecal and systemic rescue interventions aimed at rapidly reducing methotrexate concentrations and preventing severe neurotoxicity and renal failure.

THERAPEUTIC DRUG MONITORING AND DECISION SUPPORT

Therapeutic drug monitoring plays a central role in the safe administration of high-dose methotrexate. Serial measurement of plasma methotrexate levels allows early identification of delayed clearance and guides timely dose adjustments of leucovorin or glucarpidase.

Clinical decision-support tools have been developed to assist clinicians in predicting methodology of pharmacokinetics and optimizing individualized dosinstrategies.es.

11. Guidelines for MTX Nephrotoxicity

Guideline's	Year	Key Recommendations
SMO (European Society for Medical Oncology	2023	Hydrate 2-3 L/m²/day; urine pH ≥7; and check MTX levels 24-72 hours after infusion. Rescue leucovorin and glucarpidase in cases of delayed clearance.
ASCO (American Society of Clinical Oncology) /NCCN (National Comprehensive Cancer Network)	2022	Steer clear of nephrotoxic medications during HD-MTX-Leucovorin rescue depending on MTX levels; use glucarpidase in cases of AKI or delayed MTX clearance; and get regular tests for liver and kidney function.
Children's Oncology Group	2020-2023	Weight/age-based HD -MTX dosage Early monitoring of biomarkers (NGAL, KIM-1, Cystatin C) For pediatric patients, hydration and alkalinization should be modified. Protocols for rechallenge and delayed clearance should be monitored.
Japanese Society of Paediatric Hematology/Oncology	2021	Alkalinization with bicarbonate or tromethamine; leucovorin adjustment based on MTX levels; glucarpidase in cases of severe delayed clearance.
Clinical Pharmacology Consensus	2020-2024	Pharmacogenomic-guided dosage (SLCO1B1, A): Steer clear of concurrent nephrotoxins

Monitoring Procedures and Clinical Management Guidelines

Prior to HD-MTX Assess the liver and kidneys. Evaluate your level of hydration Address electrolyte imbalances.

HD-MTX

- Check the MTX levels after 24, 48, and 72 hours.
- Track pH, creatinine, and urine production.
- Maintain a pH of at least 7 and a urine production of more than 100 milliliters per hour.

Following HD-MTX

- Maintain your hydration.
- Proceed with alkalinization.
- Modify the dosage of leucovorin.
- If clearance is delayed, give glucarpidase.
- The incidence of severe nephrotoxicity is decreased by these measures.

Emerging Technologies and Opportunities Forecasting Frameworks

AI-powered machine learning algorithms for precise forecasting:

Approval by MTX Ideal dose schedules for AKI risk 13.2 **Novel Biomarkers**: Research is being conducted on: Urine microRNAs Metabolic markers that indicate endothelial damage.

Pharmacogenomics Modifications to dosage

- It may be predicated on routine genetic testing for variations in the ABCG2 and SLCO1B1 genes.

MTX Delivery Assisted by Nanotechnology Studies

- The major goals of the studies on MTX administration through nanoparticles are lessening the total toxicity in the body; improving the selectivity of the drug to tumors; and lessening the burden on the kidneys.

Instruments for Real-Time Renal Monitoring

- Technological designs worn by the developers of technology are now intended for early diagnosis for detecting AKI signs.

Current Guidance's Limitations

1. **Variability Among Guidelines:** Differences in recommendations regarding glucarpidase, leucovorin, urine pH targets, and hydration.
2. **Limited Data in Special Populations:** Genetic differences, the elderly, infants, and obese individuals are minimally represented.
3. **Biomarkers Not Completely Incorporated:** Early signs of kidney injury (NGAL, KIM1) are rarely applied.
4. **Cost and Access Issues:** Intensive monitoring and glucarpidase might not be available everywhere.
5. **Inadequate Drug Interaction Guidance:** Nephrotoxic drugs taken concurrently are often not considered.
6. **Lack of Customized Dosing:** Most recommendations are based on the general population rather than individualized.

DISCUSSION

- MTX-induced nephrotoxicity is still a major issue, even after years of clinical experience.
- Recent studies have provided support for the importance of early risk evaluation, careful hydration and alkalinization practices, and the rapid application of rescue treatments like glucarpidase.
- Personalized medicine strategies such as biomarker-based monitoring, pharmacogenomic evaluation, and AI-driven modeling characterize the future of MTX safety.
- There are still factors that limit the degree of development achieved such as the access to glucarpidase in poor-resource settings.

Unavailability and inconsistency of biomarkers

- Glucarpidase availability in low-resource environments.
- Inconsistency in the availability of biomarkers limited genetic testing in the use of nephrotoxic co-medications and the monitoring of such drugs' effects.
- Large multicenter trials are needed to universalize preventive practices.

CONCLUSION

- Methotrexate retains the considerable risk of nephrotoxicity that comes with its high doses given in cancer treatment, but it is still a very important drug. It is critical to know the mechanisms of its action, the individual risk factors of each patient, and the new developments in preventive measures to use it safely. The speeding up of research in pharmacogenomics, biomarkers, and AI-assisted prediction models has opened new doors for personalized treatment.
- Renal impairment will have to be monitored closely, or treated immediately, and taken the already established therapeutic methods will be key for getting the maximum benefit from the cancer treatment and to minimize the toxicity.

REFERENCES

1. Ghannoum M, Nolin TD, Lavergne V, Hoffman RS. Blood purification in toxicology: Nephrology's ugly duckling. *Adv Chronic Kidney Dis*, 2011; 18(3): 160–166.
2. Lavergne V, Nolin TD, Hoffman RS, Roberts D, Gosselin S, Goldfarb DS, et al. The EXTRIP (Extracorporeal Treatments in Poisoning) workgroup: Guideline methodology. *Clin Toxicol (Phila)*, 2012; 50(6): 403–413.
3. Lavergne V, Ouellet G, Bouchard J, Galvao T, Kielstein JT, Roberts DM, et al. Guidelines for reporting case studies on extracorporeal treatments in poisonings: Methodology. *Semin Dial*, 2014; 27(4): 407–414.
4. Berling I, King JD, Shepherd G, Hoffman RS, Alhatali B, Lavergne V, et al; EXTRIP Workgroup. Extracorporeal treatment for chloroquine, hydroxychloroquine, and quinine poisoning: Systematic review and recommendations. *J Am Soc Nephrol*, 2020; 31(10): 2475–2489.
5. Wong A, Hoffman RS, Walsh SJ, Roberts DM, Gosselin S, Bunchman TE, et al; EXTRIP Workgroup. Extracorporeal treatment for calcium channel blocker poisoning: Systematic review and recommendations. *Clin Toxicol (Phila)*, 2021; 59(5): 361–375.
6. Mowry JB, Shepherd G, Hoffman RS, Lavergne V, Gosselin S, Nolin TD, et al. Extracorporeal treatments for isoniazid poisoning: Systematic review and recommendations. *Pharmacotherapy*, 2021; 41(5): 463–478.

7. Henderson ES, Adamson RH, Oliverio VT. The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. *Cancer Res,* 1965; 25: 1018–1024.
8. Sand TE, Jacobsen S. Effect of urine pH and flow on renal clearance of methotrexate. *Eur J Clin Pharmacol,* 1981; 19(6): 453–456.
9. Steele WH, Lawrence JR, Stuart JF, McNeill CA. Protein binding of methotrexate by serum of normal subjects. *Eur J Clin Pharmacol,* 1979; 15(5): 363–366.
10. Rochas MA, Tufenkji AE, Levillain P, Houin G. Protein binding of methotrexate to human albumin and serum. *Arzneimittelforschung,* 1991; 41(12): 1286–1288.
11. Combe B, Edno L, Lafforgue P, Bologna C, Bernard JC, Acquaviva P, et al. Total and free methotrexate pharmacokinetics with and without piroxicam in rheumatoid arthritis. *Br J Rheumatol,* 1995; 34(5): 421–428.
12. Chládek J, Grim J, Martínková J, Simková M, Vaníčková J, Koudelková V, et al. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in psoriasis. *Br J Clin Pharmacol,* 2002; 54(2): 147–156.
13. Wan SH, Huffman DH, Azarnoff DL, Stephens R, Hoogstraten B. Effect of route of administration and effusions on methotrexate pharmacokinetics. *Cancer Res,* 1974; 34(12): 3487–3491.
14. Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. *Clin Pharmacokinet,* 1978; 3(1): 1–13.
15. Taylor ZL, Mizuno T, Punt NC, Baskaran B, Navarro Sainz A, Shuman W, et al. MTXPK.org: A clinical decision support tool for high-dose methotrexate. *Clin Pharmacol Ther,* 2020; 108(3): 635–643.
16. Ahmad S, Shen FH, Bleyer WA. Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis. *Arch Intern Med,* 1978; 138(7): 1146–1147.
17. Holmboe L, Andersen AM, Mørkrid L, Slørdal L, Hall KS. High-dose methods of chemotherapy: Pharmacokinetics and toxicity. *Br J Clin Pharmacol,* 2012; 73(1): 106–114.
18. Jardine LF, Ingram LC, Bleyer WA. Intrathecal leucovorin after intrathecal methotrexate overdose. *J Pediatr Hematol Oncol,* 1996; 18(3): 302–304.
19. Finkelstein Y, Zevin S, Heyd J, Bentur Y, Zigelman Y, Hersch M. Emergency treatment of life-threatening intrathecal methotrexate overdose. *Neurotoxicology,* 2004; 25(3): 407–410.
20. Csordas K, Hegyi M, Eipel OT, Muller J, Erdelyi DJ, Kovacs GT. Pharmacokinetics and toxicity of high-dose methotrexate in children with ALL. *Anticancer Drugs,* 2013; 24(2): 189–197.